A new study tested the investigational drug in combination with proton pump inhibitors for patients with gastroesophageal reflux disease.
Researchers have identified a potential new drug that could reduce heartburn severity in patients with treatment-resistant gastroesophageal reflux disease (GERD) when combined with a proton pump inhibitor (PPI), according to a study published in Gastroenterology.
Although PPIs are commonly used to treat GERD, approximately 30% of patients still experience symptoms despite taking their PPIs.
The safety and efficacy of IW-3718, an investigational drug that binds bile acid in the stomach, was evaluated as an adjunct to PPI therapy in a clinical study.
The study included 280 patients with confirmed GERD who received either placebo or 500, 1000, or 1500 mg of IW-3718 twice daily, with ongoing label-dose PP, from March 2016 through April 2017. Heartburn severity and regurgitation frequency was assessed.
According to the results, the main changes from baseline to week 8 in weekly heartburns severity scores showed reduction of 46% in the placebo group, 49% in the 500-mg group, 55.1% in the 1000-mg group, and 58% in the 1500-mg group (dose-response P=.02). The treatment difference was 11.9% between the 1500-mg IW-3718 group and the placebo groups (P=.04, analysis of covariance).
For weekly regurgitation frequency in the 1500-mg group versus the placebo group, there was a 17.5% reduction (95% CI, reductions of 31.4% to 3.6%).
IW-3718 was also generally well tolerated, with the most common adverse event (AE) being constipation. There were no drug-related serious AEs.
“These data provide strong evidence that bile acid plays a key role in refractory GERD and that IW-3718 may have the potential to make a meaningful difference for patients,” Michael Vaezi, MD, PhD, MSc, director of the Center for Swallowing and Esophageal Disorders at Vanderbilt University Medical Center, said in a press release about the study.
1. Vaezi MF, Fass R, Vakil N, et al. IW-3718 reduces heartburn severity in patients with refractory gastroesophageal reflux disease in a randomized trial. Gastroenterology. 2020. DOI: https://doi.org/10.1053/j.gastro.2020.02.031
2. Potential new heartburn drug studied at VUMC [news release]. VUMC’s website. https://news.vumc.org/2020/02/26/potential-new-heartburn-drug-studied-at-vumc/. Accessed February 26, 2020.
Pharmacy practice is always changing. Stay ahead of the curve with the Drug Topics newsletter and get the latest drug information, industry trends, and patient care tips.